WHAT DID THE CASS REVIEW FIND?
The Cass Review is an independent review of gender identity services for children and young people in England, published in April 2024. Its central finding was that the evidence base for puberty-pausing medication and hormones in young people is weak, meaning of low certainty. It is essential to be precise about what that means: the Review concluded that the quality of the research is low, not that the care was shown to be harmful. Low certainty in a body of evidence describes gaps and limitations in the studies, and it is a different thing from evidence of harm. The Review recommended a more cautious, holistic approach, and it led to changes in England's health service. Major US medical organizations reviewed its conclusions and reaffirmed their support for the care, and researchers continue to weigh the Review differently.
Because the Cass Review is often cited in public debate, and sometimes stretched beyond what it actually says, it helps to see clearly what it is, what it found, what it recommended, and how medical bodies and researchers have responded. This page lays that out, with sources on more than one side.
Scope and terminology note: The Cass Review concerns England's National Health Service, so it is a review of care in the United Kingdom. It is included here because it is directly relevant to the evidence discussion in the United States. This page uses "puberty-pausing medication" for the treatment sometimes called puberty blockers.
CONTENT NOTE
This is information, not medical advice, and it explains a clinical scale rather than any individual's care. Whether and when any medication is appropriate for a particular young person is a decision for that young person, their family, and their qualified healthcare providers, and in nearly all cases minors cannot receive it without parental consent. If you are in immediate danger, call 911; for support any time, call or text 988.
-
An independent NHS review. The Cass Review examined gender services for young people in England and published its final report in April 2024.
-
Its finding was about evidence quality. It concluded the evidence for puberty-pausing medication and hormones in youth is weak, or low-certainty.
-
Low certainty is not evidence of harm. The Review did not find that the care causes harm; it found the research supporting benefit is of low quality.
-
It recommended caution, not bans. It recommended puberty-pausing medication only within research, and it did not recommend legislative bans.
-
US bodies reaffirmed support. Major US medical organizations reviewed its conclusions and continue to regard the care as evidence-based.
KEY TAKEAWAYS
WHAT THE CASS REVIEW IS
​
The Cass Review is an independent review commissioned by England's National Health Service to examine gender identity services for children and young people, led by the pediatrician Dr Hilary Cass. Commissioned in 2020, it published its final report in April 2024, after about three and a half years of work. It drew on a series of systematic reviews of the research literature commissioned from the University of York, which examined the characteristics of young people seeking care, the effects of social transition, and the evidence for puberty-pausing medication and hormones, and it evaluated existing international treatment guidelines. It is a substantial and serious piece of work, and it has been influential.
WHAT THE CASS REVIEW FOUND
The Review's central conclusion was that the evidence supporting puberty-pausing medication and hormones for young people is weak, meaning of low quality or certainty, and that high-quality long-term evidence is lacking. The final report concluded that the evidence on the use of these medications for mental or psychosocial health is weak, and that there is a lack of high-quality studies. It also found there was insufficient evidence to determine whether social transition in childhood has positive or negative effects on mental health. The systematic reviews behind the report identified few studies they rated as high quality.
It is important to read this carefully. A finding that evidence is of low certainty is a statement about the design and quality of the available studies, many of which are observational and without control groups. It is not a finding that the care has been shown to be harmful, and the Review did not conclude that it had.
WHAT THE CASS REVIEW RECOMMENDED
The Review recommended a more cautious and holistic approach, including limiting puberty-pausing medication to research settings, while notably not recommending that the care be banned.
Following the report, England's National Health Service halted new prescriptions of puberty-pausing medication outside of research and restricted hormone provision. One point often lost in US debate is that, as even a peer-reviewed analysis critical of the Review's critics confirms, the Cass Review did not recommend legislative bans on this care for adolescents. Its recommendations concerned how care should be delivered and studied, not prohibition.
THE CRUCIAL DISTINCTION: LOW CERTAINTY
IS NOT EVIDENCE OF HARM
The single most important thing to understand about the Cass Review is that "low certainty of evidence" and "evidence of harm" are not the same thing. When a review rates evidence as low-certainty, it is saying the studies are not designed well enough to be confident about the size of the benefit, usually because they are observational rather than randomized. That is a real limitation, and it is worth taking seriously. It is not, however, a finding that a treatment is harmful or ineffective. Many accepted treatments across pediatric medicine rest on evidence that formal grading tools would also rate as low-certainty, because randomized trials are often difficult or unethical to run in children. Reading "weak evidence" as "proven harm" misstates what the Review, and this kind of evidence grading, actually means.
HOW U.S. MEDICAL BODIES RESPONDED
Major US medical and mental-health organizations reviewed the Cass Review's conclusions and reaffirmed their support for this care. The American Academy of Pediatrics reaffirmed its policy and commissioned its own systematic review of the evidence, and the Endocrine Society reaffirmed its clinical guidance. Alongside the American Medical Association and American Psychological Association, these bodies continue to regard the care as evidence-based and medically necessary. They are aware of the evidence limitations the Review describes and, weighing them alongside clinical experience and the risks of withholding care, reach a different conclusion about how to act. This medical-society response is an essential part of the picture whenever the Cass Review is discussed.
THE SCIENTIFIC CRITIQUES
A number of clinician-researchers have published critiques of the Cass Review, arguing mainly that it set an unusually high bar for evidence and discounted observational research that is standard elsewhere in medicine. A critical commentary in the International Journal of Transgender Health argued that the Review's handling of the evidence was open to challenge and that its recommendations went further than the underlying reviews required. Critics have also noted that discounting observational studies, as the Review's approach tended to do, sets a standard much of pediatric care could not meet.
At the same time, the debate is not one-sided. A peer-reviewed analysis of these critiques found that some criticisms of the Review were overstated, while agreeing with critics on other points, including that the Review did not recommend bans, that long waiting times are a real problem, and that long-term outcome data are genuinely lacking. In other words, thoughtful people disagree about how much weight the Cass Review should carry, and some of its underlying concerns, about thin long-term evidence and the need for holistic care, are widely shared even by those who disagree with its conclusions.
HOW TO READ THE CASS REVIEW
The most accurate way to understand the Cass Review is as a serious, independent assessment that reached a cautious conclusion about the certainty of the evidence, and as one input into an ongoing scientific discussion rather than the final word. It is not proof that the care is harmful, and it did not find that. It is also not something to be dismissed; its concerns about long-term data and holistic care are real. What it represents is genuine disagreement about how to weigh limited evidence, the same disagreement that runs through this whole area. For how that plays out on specific questions, see: are puberty blockers safe and the risks of gender-affirming hormones, and for what the research associates with better outcomes, gender-affirming care and mental health outcomes.